Not Signed In -
Gamma Knife Treatment |
|
|
Clinical Trial: An Open-label study of the safety and efficacy of subcutaneous recombinant interferon-gamma 1b (IFN-gamma 1b) in patients with Idiopathic Pulmonary Fibrosis (IPF)
This study is no longer recruiting patients.
|
Purpose
Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Lung Disease Pulmonary Fibrosis | Drug: interferon-gamma 1b | Phase III |
MedlinePlus related topics: Pulmonary Fibrosis; Respiratory Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Expected Total Enrollment: 210
Study start: September 2002
Eligibility
Ages Eligible for Study: 20 Years - 79 Years, Genders Eligible for Study: Both
Criteria
Male or Female
Idiopathic Pulmonary Fibrosis
20-79 years
Must have participated in the InterMune protocol GIPF-001 study.
Location Information
Washington
University of Washington Medical Center, Seattle, Washington, 98195, United States
More Information
Record last reviewed: December 2003
Last Updated: October 13, 2004
Record first received: January 21, 2003
ClinicalTrials.gov Identifier: NCT00052052
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
